Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model

International Journal of Antimicrobial Agents

Volumn 31, Issue 2, 2008, Pages 158-160

  Hamel, Antoine ^a   Caillon, Jocelyne ^a   Jacqueline, Cédric ^a   Batard, Eric ^a   Potel, Gilles ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Arthritis; Quinupristin dalfopristin; Staphylococcus aureus

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; RIFAMPICIN; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHRITIS; ARTICLE; BONE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFECTIOUS ARTHRITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RABBIT;

EID: 37649019600     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.09.004     Document Type: Article

References (9)

1. Appelbaum P.C. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 12 (2006) 16-23
2. Sambatakou H., Giamarellos-Bourboulis E.J., Grecka P., Chryssouli Z., and Giamarellou H. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother 41 (1998) 349-355
3. Batard E., Jacqueline C., Boutoille D., et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob Agents Chemother 46 (2002) 2174-2178
4. Saleh-Mghir A., Ameur N., Muller-Serieys C., et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 46 (2002) 1122-1124
5. Amsterdam D. Susceptibility testing of antibiotics in liquid media. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 4th ed. (1996), Williams and Wilkins Co, Baltimore, MD 52-111
6. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279 (1998) 1537-1541
7. Drew R.H., Perfect J.R., Srinath L., Kurkimilis E., Dowzicky M., and Talbot G.H. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 46 (2000) 775-784
8. Moellering R.C. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother 44 Suppl. A (1999) 25-30
9. Paterson D.L. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 6 (2006) 486-490